MLC1 and GlialCAM have been shown to regulate cell motility and proliferation in various cell lines, and dysregulation of these proteins, as well as their newly identified interaction partner GPRC5B (Alonso‐Gardón et al. 2021; Passchier et al. 2023), has been implicated in cancer (Lanciotti et al. 2016; Hwang et al. 2019; Lattier et al. 2020; Kanamori et al. 2023; Wu et al. 2024). Here, GPRC5B is linked to cancer.